Apollon Wealth Management LLC Has $2.20 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Apollon Wealth Management LLC trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 5,330 shares of the company’s stock after selling 2,027 shares during the period. Apollon Wealth Management LLC’s holdings in IDEXX Laboratories were worth $2,204,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. FSA Wealth Management LLC bought a new position in IDEXX Laboratories during the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares in the last quarter. Finally, Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories during the third quarter worth about $37,000. 87.84% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on IDXX. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Piper Sandler restated a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Leerink Partners started coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target on the stock. Finally, Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $524.38.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 0.2 %

NASDAQ IDXX opened at $459.78 on Monday. The company has a market cap of $37.65 billion, a price-to-earnings ratio of 43.09, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business’s fifty day moving average is $428.35 and its 200 day moving average is $453.44.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.